Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.
about
Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsGuidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerIn vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agentsDose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits.In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis.A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of thePopulation pharmacokinetics of amphotericin B lipid complex in neonates.Canadian clinical practice guidelines for invasive candidiasis in adults.Antifungal agents for the treatment of systemic fungal infections in children.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Human pharmacogenomic variations and their implications for antifungal efficacy.Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Pediatric Invasive Candidiasis: Epidemiology and Diagnosis in Children.Les antifongiques pour le traitement des infections fongiques systémiques chez les enfants.
P2860
Q27025299-38A2BCFF-8CC3-4C11-996E-F9D6FB0FEF6AQ33650105-0E5567BA-FA2A-43A6-B158-AA5F689D13AFQ33692198-CC199729-94FE-48E7-8A00-5DE33128C0C0Q33977417-CDA014F6-8415-4298-A3D3-C140E2663135Q33980180-2A711BB5-161A-4FB2-ADB2-326EA51D71E6Q33980705-F52F7462-5DC0-4B8C-9707-921587220725Q33980885-0A328606-E578-4F6E-BBA1-1E858A698673Q34212799-16714B61-1B67-4A87-8753-9F30E9404DF0Q34228332-8A59ABA8-EE72-46FC-AD65-7CEE5724BF1DQ34237335-0509A3F9-85B7-4BA4-B469-26FFCB0CB082Q34437094-2FAA86A7-6A2E-4F67-885D-393A16A2BEDAQ34505582-8BB6ECC9-90AC-444E-8FD3-891A2A1420B0Q35070838-28837D39-9F2B-427A-89F8-B8E3048477B9Q37469829-43DF9715-2920-4412-86CC-2AAA1E54278CQ49182676-16CF9059-5465-4B42-A2BE-7C7E0ADDAC96Q55461573-79C2A490-48A9-4CCA-9933-48016E1EB88B
P2860
Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.
description
1997 nî lūn-bûn
@nan
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Safety, tolerance, and pharmac ...... ith hepatosplenic candidiasis.
@ast
Safety, tolerance, and pharmac ...... ith hepatosplenic candidiasis.
@en
type
label
Safety, tolerance, and pharmac ...... ith hepatosplenic candidiasis.
@ast
Safety, tolerance, and pharmac ...... ith hepatosplenic candidiasis.
@en
prefLabel
Safety, tolerance, and pharmac ...... ith hepatosplenic candidiasis.
@ast
Safety, tolerance, and pharmac ...... ith hepatosplenic candidiasis.
@en
P2093
P2860
P356
P1476
Safety, tolerance, and pharmac ...... with hepatosplenic candidiasis
@en
P2093
Chanock SJ
Jarosinski P
Piscitelli S
Whitcomb P
P2860
P304
P356
10.1128/AAC.41.9.1944
P407
P577
1997-09-01T00:00:00Z